Point72 Asset Management L.P. acquired a new stake in Nightstar Therapeutics PLC (NASDAQ:NITE) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,527,229 shares of the company’s stock, valued at approximately $31,201,000. Point72 Asset Management L.P. owned 5.43% of Nightstar Therapeutics as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in NITE. Redmile Group LLC raised its position in Nightstar Therapeutics by 16.5% during the 3rd quarter. Redmile Group LLC now owns 2,080,846 shares of the company’s stock valued at $42,512,000 after purchasing an additional 295,400 shares during the last quarter. Renaissance Technologies LLC bought a new position in Nightstar Therapeutics during the 3rd quarter valued at approximately $1,669,000. Citadel Advisors LLC bought a new position in Nightstar Therapeutics during the 3rd quarter valued at approximately $1,368,000. Tekla Capital Management LLC purchased a new position in shares of Nightstar Therapeutics during the 3rd quarter worth approximately $3,065,000. Finally, Monashee Investment Management LLC purchased a new position in shares of Nightstar Therapeutics during the 3rd quarter worth approximately $1,430,000. 37.84% of the stock is owned by hedge funds and other institutional investors.
NITE stock opened at $11.64 on Friday. Nightstar Therapeutics PLC has a fifty-two week low of $9.59 and a fifty-two week high of $29.55.
NITE has been the topic of a number of research analyst reports. Cantor Fitzgerald initiated coverage on Nightstar Therapeutics in a report on Thursday, October 11th. They set an “overweight” rating and a $36.00 target price on the stock. BMO Capital Markets set a $41.00 target price on Nightstar Therapeutics and gave the stock a “buy” rating in a report on Monday, September 24th. Janney Montgomery Scott initiated coverage on Nightstar Therapeutics in a report on Wednesday, August 22nd. They set a “buy” rating and a $34.00 target price on the stock. Leerink Swann upped their target price on Nightstar Therapeutics from $30.00 to $35.00 and gave the stock a “positive” rating in a report on Monday, September 24th. Finally, Mizuho upped their target price on Nightstar Therapeutics to $24.00 and gave the stock a “buy” rating in a report on Tuesday, September 4th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $32.00.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/12/16/point72-asset-management-l-p-acquires-shares-of-1527229-nightstar-therapeutics-plc-nite.html.
About Nightstar Therapeutics
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.
Featured Story: How accurate is the Rule of 72?
Want to see what other hedge funds are holding NITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nightstar Therapeutics PLC (NASDAQ:NITE).
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.